medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (2)


Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation: A Retrospective Cohort Study

Karvellas CJ, Cardoso FS, Senzolo M, Wells M, Alghanem MG, Handou F, Kwapisz L, Kneteman NM, Marotta PJ, Al-Judaibi B

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 236-246
Archivo PDF: 213.48 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010; 16: 83-90.

  2. Ravaioli M, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Cucchetti A, et al. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg 2011; 253: 378-84.

  3. Gayowski TJ, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, Wagener M, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60: 333-8.

  4. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D’Andrea G, Marmo R, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-8.

  5. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-41.

  6. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.

  7. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010; 16: 999-1005.

  8. Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, et al. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg 2002; 235: 292-6.

  9. Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant 2002; 2: 934-8.

  10. Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, et al. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg 2014; 259: 760-6.

  11. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-51.

  12. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11: 459-64.

  13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-8.

  14. Association WM. Declaration of Helsinki - Ethical Principles for Medical Research involving Human subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/

  15. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90.

  16. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37, 1437 e1-9.

  17. UNOS. MELD/PELD Calculator Documentation. Available at: https://www.unos.org/wp-content/uploads/unos/MELD_PELD _Calculator_Documentation.pdf

  18. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, et al. MELD Exceptions and Rates of Waiting List Outcomes. Am J Transplant 2011; 11: 2362-71.

  19. Parvey HR, Raval B, Sandler CM. Portal vein thrombosis: imaging findings. Am J Roentgenol 1994; 162: 77-81.

  20. Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, Mayer D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69: 1873-81.

  21. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, De Nucci C, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535-8.

  22. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-43.

  23. Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. Transplantation 2015.

  24. Berry K, Taylor J, Liou IW, Ioannou GN. Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 585-93.

  25. Rodriguez-Castro KI, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation 2012; 94: 1145-53.

  26. Charlton M, Gane E, Manns MP, Brown RS, Jr., Curry MP, Kwo PY, Fontana RJ, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.

  27. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Jr., Fenkel JM, Gordon F, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107 e1.

  28. Arshad F, Lisman T, Porte RJ. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Liver Int 2013; 33: 820-7.

  29. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51(4): 682-9.

  30. Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia- Criado A, Abraldes JG, et al. Efficacy and safety of anti coagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-83.

  31. Senzolo M, Santori, TM, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-27.




2020     |     www.medigraphic.com